Jan 13, 2018 ProMIS Alzheimer’s Therapy Attacks Only Harmful Brain Protein, Unlike Other Treatments, Study Finds
Nov 29, 2017 Routes are opening up potentially to prevent or reverse damage that leads to the disease
Oct 17, 2017 ProMIS Neurosciences Lead Product Candidate, PMN310, Shows Desired Target Binding Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies for Alzheimer's Disease
Sep 19, 2017 ProMIS Neurosciences could have a groundbreaking Alzheimer’s treatment, Mackie Research says
Sep 13, 2017 Reuters: BRIEF-ProMIS Neurosciences designates PMN330 as 3rd, validated lead product for development in alzheimer’s disease